Business Wire

LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

25.7.2022 17:35:00 EEST | Business Wire | Press release

Share

LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

  • in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU));
  • in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX.

Denis Delval, LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the approval of CEVENFACTA ® by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union. This approval is a validation of our innovative LFB technology and the acknowledgement of LFB’s deep commitment to patients.”

Dr. Patrick Delavault, MD, LFB’s Executive Vice President Scientific, Medical and Regulatory Affairs, stated: “We need to keep in mind constantly what a bleeding event, even a single bleeding event, means to a haemophilia patient with inhibitors and to his family. This novel treatment alternative is a significative opportunity to improve patients’ lives”.

LFB has been granted a Marketing Authorisation for SEVENFACT® (eptacog beta) in Mexico on June 2nd for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors.

About PERSEPT studies:

The approval of CEVENFACTA® was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.

The PERSEPT 1 Phase III, multicentre, randomised, open-label crossover study of two initial dose regimens (75µg/kg and 225µg/kg), evaluated 468 bleeding episodes across the full type of severity of bleeding episodes (mild, moderate, and severe), in 27 adolescent and adult haemophilia A and B patients with inhibitors (12-54 years of age). Both dosing regimens met the primary endpoint with 81% and 90% of bleeds controlled at 12 hours with the 75µg/kg dose and the 225µg/kg dose respectively. By 24 hours, haemostatic efficacy (secondary endpoint) was retained in 96.7% of bleeding episodes treated with the 75 µg/kg dose regimen and 99.5% of redundancy bleeding episodes treated with the 225 µg/kg dose, without requiring any alternative therapy. The median time to attain haemostatic efficacy was 5.98 hours for the 75 µg/kg dosing regimen and 3 hours for the 225 µg/kg dosing regimen. A median of 2 injections was needed to treat a bleeding episode with the 75 µg/kg and a median of only 1 injection of the 225 µg/kg dosing regimen was needed.

The PERSEPT 3 Phase III, multicentre, open-label, single-arm study evaluated the safety and efficacy of CEVENFACTA® in haemophilia A or B patients with inhibitors who were scheduled for an elective surgical or other invasive procedure. 12 patients were enrolled in the study, 6 with minor procedures and 6 with major procedures. For major surgical/invasive procedures, treatment was administered at an initial bolus dose of 200 µg/kg immediately before the start of the invasive procedure. For a minor elective surgical procedure, an initial bolus dose of 75 µg/kg was administered immediately before the start of the procedure. Overall, 81.8% of procedures were reported as successfully treated at 48 hours after the last administration of the product.

No thromboembolic events were reported in these two clinical trials. No Serious Adverse Events (SAEs) were considered as related to the treatment.

Patients should be monitored for any signs of thrombosis, hypersensitivity and neutralising antibodies. The most frequently reported adverse reactions in studies were infusion site discomfort, infusion site haematoma, post-procedural haematoma, infusion related reaction, increased body temperature, dizziness and headache.

About LFB

LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care.

LFB currently markets 15 biomedicinal products in more than 30 countries.

Please visit www.groupe-lfb.com for further information on LFB.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LFB Contact:
Didier Véron - Executive Vice President, Corporate Affairs
Tel: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54
verondidier@lfb.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 15:08:00 EET | Press release

Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 15:00:00 EET | Press release

GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119117575/en/ Representative pre- and post-mangaciclanol images in patients from the LUMINA Phase 2/3 trial

Ehime CATV expands public-sector connectivity in Japan with Adtran XGS-PON technology19.11.2026 15:00:00 EET | Press release

Adtran today announced that Ehime CATV has selected its XGS-PON technology to support a new broadband network for public schools and local government offices in Ehime Prefecture, Japan. The deployment will provide 10Gbit/s connectivity to more than 100 public-sector sites, supporting digital learning, cloud-based applications and everyday online services for students, teachers and municipal users. With its compact footprint and flexible expansion model, Adtran’s access technology will help Ehime CATV transition beyond legacy EPON infrastructure to ITU-based XGS-PON. The upgrade will also support a more diversified supplier strategy, helping mitigate geopolitical supply chain risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119028160/en/ Adtran’s XGS-PON technology is helping Ehime CATV develop a new broadband network for public schools and local government offices. “Supporting the communities we serve has always been

Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 15:00:00 EET | Press release

Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie

Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release

At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye